



Article Chemical Constituents of Macaranga occidentalis, Antimicrobial and Chemophenetic Studies

Viviane Flore Kamlo Kamso¹, Christophe Colombe Simo Fotso², Ines Michèle Kanko Mbekou³, Billy Tchegnitegni Tousssie⁴, Bruno Ndjakou Lenta⁵, Fabrice Fekam Boyom³, Norbert Sewald^{6,*}, Marcel Frese⁶, Bonaventure Tchaleu Ngadjui¹ and Ghislain Wabo Fotso^{1,6,*}

- ¹ Department of Organic Chemistry, Faculty of Science, University of Yaoundé I, Yaoundé P.O. Box 812, Cameroon
- ² Department of Chemistry, Faculty of Science, University of Buea, Buea P.O. Box 63, Cameroon
- ³ Department of Biochemistry, Faculty of Science, University of Yaoundé I, Yaoundé P.O. Box 812, Cameroon
- ⁴ Department of Chemistry, Faculty of Science, University of Dschang, Dschang P.O. Box 67, Cameroon
- ⁵ Department of Chemistry, Higher Teacher Training College, University of Yaoundé I, Yaoundé P.O. Box 47, Cameroon
- ⁶ Department of Chemistry, Organic and Bioorganic Chemistry, University of Bielefeld, 33501 Bielefeld, Germany
- * Correspondence: norbert.sewald@uni-bielefeld.de (N.S.); ghislain.fotso@uni-bielefeld.de (G.W.F.)

Abstract: Medicinal plants are known as sources of potential antimicrobial compounds belonging to different classes. The aim of the present work was to evaluate the antimicrobial potential of the crude extract, fractions, and some isolated secondary metabolites from the leaves of Macaranga occidentalis, a Cameroonian medicinal plant traditionally used for the treatment of microbial infections. Repeated column chromatography of the ethyl acetate and n-butanol fractions led to the isolation of seventeen previously known compounds (1-17), among which three steroids (1-3), one triterpene (4), four flavonoids (5-8), two stilbenoids (9 and 10) four ellagic acid derivatives (11-14), one geraniinic acid derivative (15), one coumarine (16), and one glyceride (17). Their structures were elucidated mainly by means of extensive spectroscopic and spectrometric (1D and 2D NMR and, MS) analysis and comparison with the published data. The crude extract, fractions, and isolated compounds were all screened for their antimicrobial activity. None of the natural compounds was active against Candida strains. However, the crude extract, fractions, and compounds showed varying levels of antibacterial properties against at least one of the tested bacterial strains, with minimal inhibitory concentrations (MICs) ranging from 250 to 1000 μ g/mL. The *n*-butanol (*n*-BuOH) fraction was the most active against Escherichia coli ATCC 25922, with an MIC value of 250 µg/mL. Among the isolated compounds, schweinfurthin B (10) exhibited the best activity against Staphylococcus aureus NR 46003 with a MIC value of $62.5 \,\mu\text{g/mL}$. In addition, schweinfurthin O (9) and isomacarangin (6) also exhibited moderate activity against the same strain with a MIC value of $125 \,\mu\text{g/mL}$. Therefore, pharmacomodulation was performed on compound 6 and three new semisynthetic derivatives (6a-c) were prepared by allylation and acetylation reactions and screened for their in vitro antimicrobial activity. None of the semisynthetic derivatives showed antimicrobial activity against the same tested strains. The chemophenetic significance of the isolated compounds is also discussed in this paper.

Keywords: *Macaranga occidentalis;* prenylated flavonoids; stilbenes; antimicrobial activity; pharmacomodulation; chemophenetic significance

1. Introduction

Infectious diseases caused by bacteria, viruses, fungi, and other parasites continue to cause enormous damage worldwide. Bacterial infections kill over seven million people annually, and they may kill up to 10 million people by the year 2050 if appropriate measures are not taken [1]. The high rate of bacterial resistance to available antibiotics is alarming and



Citation: Kamso, V.F.K.; Simo Fotso, C.C.; Kanko Mbekou, I.M.; Tousssie, B.T.; Ndjakou Lenta, B.; Boyom, F.F.; Sewald, N.; Frese, M.; Ngadjui, B.T.; Wabo Fotso, G. Chemical Constituents of *Macaranga occidentalis*, Antimicrobial and Chemophenetic Studies. *Molecules* **2022**, *27*, 8820. https://doi.org/10.3390/ molecules27248820

Academic Editor: Francesco Cacciola

Received: 12 November 2022 Accepted: 9 December 2022 Published: 12 December 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). makes the treatment of even simple bacterial infections difficult [2]. This resistance could be due to the capacity of Gram-positive or Gram-negative bacteria to acquire resistance mechanisms to face environmental aggression such as competing bacteria, the natural environment, host defense, or antibiotics, either by modification of the anti-infective active sites or by the production of degradative enzymes [3]. This concern requires a continuous search for new and efficient lead antibacterial agents to fight against multiresistant microbial agents and to limit undesirable side effects. Plants have long been reported as important sources of bioactive molecules [4]. Plants of the Macaranga genus of the Euphorbiaceae are commonly used by traditional healers for the treatment of various diseases such as swellings, cuts, sores, diarrhea, cough, stomach-ache, hypertension, boils, furuncles, and bruises [5–8]. Macaranga occidentalis (Müll.Arg.) Müll.Arg. is used in the western region of Cameroon to treat stomach wash for pregnant women. Previous pharmacological studies of the crude extracts, fractions, and isolated compounds of the Macaranga genus possess a wide range of biological activities including anticancer, antioxidant, anti-inflammatory, and antimicrobial activities [5]. Chemical investigations of plants of this genus indicate that they constitute a rich source of isoprenylated, geranylated, and farnesylated flavonoids and stilbenes [7,8], terpenoids [9], coumarins [10], ellagic acid derivatives, and tannins [11]. As part of our long-term research work on bioactive natural product medicinal plants [12,13], we examined the leaves of *M. occidentalis* growing in Cameroon. We herein report the antimicrobial potential of the crude extract, ethyl acetate (EtOAc), and *n*-BuOH fractions of this plant from which seventeen naturally occurring compounds were isolated and screened. In addition, three new semisynthetic derivatives were prepared and screened for their in vitro antimicrobial potential. To the best of our knowledge, this work also provides the first chemical and biological investigation of *M. occidentalis* as well as the chemophenetic significance of the isolated compounds.

2. Results and Discussion

2.1. Isolation of Specialized Metabolites from M. occidentalis

The DCM–MeOH (1:1, v/v) extract from the leaves of *M. occidentalis* was subjected to liquid–liquid partition with EtOAc and *n*-BuOH. Repeated column chromatography on silica gel and Sephadex LH-20 of these fractions afforded 17 known metabolites (1–17) (Figure 1). Their structures were established by spectroscopic (1D and 2D NMR) and spectrometric analysis and by comparison with the literature data as a mixture of β -sitosterol and stigmasterol (1 and 2) [14], β -sitosterol-3-*O*- β -*D*-glucopyranoside (3) [15], lupeol (4) [16], apigenin-7-*O*- β -*D*-glucopyranoside (5) [17], isomacarangin (6) [6], kaempferol (7) [18], quercetin (8) [18]; schweinfurthin O (9) [8], schweinfurthin B (10) [19], ellagic acid (11) [11], 3,4-methylenedioxy-3'-O-methylellagic (12) [20], 3,3',4-tri-O-methylellagic acid 4'-O- β -D-glucopyranoside (13) [21], 3,3',4'-tri-O-methylellagic acid (14) [22], (5*R*,6*R*)-4,6-dihydrocarbonyl-5-[2',3',4'-trihydroxy-6'-(methoxycarbonyl)phenyl]-5,6-dihydro-2H-pyran-2-one (15) [23], methyl brocchllin carboxy-late (16) [24], and ishigoside (17) [25].



Figure 1. Structures of the isolated compounds (1–17) from *M. occidentalis*.

2.2. Antimicrobial Activity of the Extract, Fractions, and Isolated Compounds

The results of the in vitro antibacterial activities of the DCM-MeOH (1:1, v/v) extract, EtOAc and *n*-BuOH fractions as well as the isolates and semisynthetic compounds are presented in Table 1. All extracts and fractions showed varying levels of antibacterial properties against at least one of the tested bacterial strains, with MICs ranging from 250 to 1000 μ g/mL. The antibacterial activity of the plant extract and fraction can be classified as significant (MIC <100 μ g/mL), moderate (100 < MIC < 625 μ g/mL) and weak (MIC > 625 μ g/mL) [26]. According to this classification, the inhibitory potential of the screened extract and fractions could be considered moderate to weak. The *n*-BuOH $(MIC = 250 \ \mu g/mL)$ fraction was the most active against *Escherichia coli* ATCC 25922, followed by the MeOH extract (MIC = 500–1000 μ g/mL), which displayed activity against Staphylococcus aureus NR 46003, Escherichia coli ATCC 25922, and Shigella flexneri NR 518. Additionally, the EtOAc fraction also showed moderate activity (MIC = $500 \,\mu\text{g/mL}$) against Escherichia coli ATCC 25922. The results obtained present the differences between the antibacterial activities of the extract and fractions from the *M. occidentalis* leaves. This suggests that the plant contains several active principles with different polarities, as shown by the nature of the isolates. Indeed, the antibacterial activity of medicinal plants is correlated with their chemical composition [3]. The *n*-BuOH fraction was the most active against Escherichia coli ATCC 25922, but all of the isolated compounds from this fraction presented weak or no activity against the selected strains, which could be due to the synergetic effect of the different constituents of this fraction. However, the purification of the EtOAc fraction

afforded more active compounds (6, 8, 9, and 10) against Staphylococcus aureus NR 46003 and Shigella flexneri NR 518 and suggested the antagonist effect of compounds in this fraction. EtOAc is a semipolar solvent and can effectively extract semipolar active compounds such as flavonoids, stilbenes, terpenoids, and ellagic acids, which are well-known to have a broad spectrum of activity against bacterial strains [27]. The results obtained herein are in agreement with those reported in the literature [28,29], which present the antimicrobial potential of the methanolic extracts of M. gigantea, M. pruinosa, M. tanarius, and M. triloba using the disc-diffusion method against Gram-positive bacteria (Bacillus cereus, Micrococcus luteus and, Staphylococcus aureus) and Gram-negative bacteria (Escherichia coli, Klebsiella pneumoniae and, Salmonella choleraius). In this study, all the Macaranga extracts exhibited moderate inhibition diameters and only for Gram-positive species. Similar results were obtained by Salah et al. (2003) after screening of the Cameroonian M. monandra, which showed that it was also inactive against *C. acutatum*, *C. gloeosporioides*, and *C. fragariea* [30]. Our results not only validate the use of *M. occidentalis* in folk medicine to treat related diseases, but also support previous literature results from plants of this genus. Regarding the pure compounds, their antimicrobial activity can be classified as significant (MIC <10 μ g/mL), moderate ($10 < MIC < 100 \ \mu g/mL$), or weak (MIC > $100 \ \mu g/mL$) [26]. According to this point, the isolates showed inhibition ranging from moderate to weak. Schweinfurthin B (10), which exhibited moderate activity against Staphylococcus aureus NR 46003 with a MIC value of 62.5 μ g/mL, was the most active. Furthermore, schweinfurthin O (9) and isomacarangin (6) similar to schweinfurthin B (10), which belong to the C-prenylated phenolic compounds, exhibited moderate activity against the same strain with a MIC value of 125 μ g/mL. These results are in agreement with those in the literature, which indicated that the presence of C-prenyl groups in flavonoids and other phenolic compounds played an important effect on the inhibitory activity against bacterial strains [31]. In addition, the good activity of compound 6 (MIC = $125 \,\mu\text{g/mL}$) compared to those of 7 and 8, which also belong to flavonoids, is not surprising, since it has been reported that C-prenylated flavonoids are more hydrophobic than common flavonoids, facilitating the ability to penetrate the cell membrane, thus improving their action at the active site [32].

Compounds	KP NR 41897	PA NR 48982	SA NR 46003	EC ATCC 25922	SF NR 518	CA NR-29340	CK HM-1122	CG NR-51685
3	>500	>500	>500	>500	>500	>500	>500	>500
4	>500	>500	>500	>500	>500	>500	>500	>500
5	>500	>500	>500	>500	>500	>500	>500	>500
6	>500	>500	125	>500	500	>500	>500	>500
7	>500	>500	>500	>500	>500	>500	>500	>500
8	>500	>500	250	>500	250	>500	>500	>500
9	>500	>500	125	>500	500	>500	>500	>500
10	>500	>500	62.5	>500	>500	>500	>500	>500
11	>500	>500	>500	>500	>500	>500	>500	>500
12	>500	>500	>500	>500	>500	>500	>500	>500
13	>500	>500	>500	>500	>500	>500	>500	>500
15	>500	>500	>500	>500	>500	>500	>500	>500
16	>500	>500	>500	>500	>500	>500	>500	>500
17	250	>500	>500	500	>500	>500	>500	>500
6a	>500	>500	>500	>500	>500	>500	>500	>500
6b	>500	>500	>500	>500	>500	>500	>500	>500
6c	>500	>500	>500	>500	>500	>500	>500	>500

Table 1. Minimum inhibitory concentrations (MICs) (μ g/mL) of compounds 3–13, 15–17, and 6a–c.

Compounds	KP NR 41897	PA NR 48982	SA NR 46003	EC ATCC 25922	SF NR 518	CA NR-29340	CK HM-1122	CG NR-51685
DCM/MeOH (1:1) EtOAc <i>n</i> -BuOH Ciprofloxacin	>1000	1000 >1000 >1000 0.015	500 1000 1000 0.031	1000 500 250 0.015	500 1000 1000 0.031	>2000 500 1000	>2000 >2000 2000	>2000 >2000 2000
Fluconazole		0.010	0.001	0.010	0.001	0.0625	0.0765	0.153

Table 1. Cont.

PA NR 48982: Pseudomonas aeruginosa; SA NR 46003: Staphylococcus aureus; KP NR 41897: Klebsiella pneumoniae; SF NR 518: Shigella flexneri; EC ATCC 25922: Escherichia coli; CA NR-29340: Candida albicans, CK HM-1122: Candida krusei, CG NR-51685: Candida glabrata; >1000—>500: non active.

2.3. Alkylation and Acylation of Compound **6**: Semisynthesis of Alkylated, and Acylated Derivatives **6a–c**

Lipophilicity is an important factor for the absorption of a drug candidate through the membrane of a microbe. Lipophilic groups such as allyl or prenyl groups have been demonstrated to enhance access and affinity or inhibit RAS transduction [33–35]. Therefore, compound **6**, showing moderate antimicrobial activity, was allylated under weakly basic conditions, yielding two allylated derivatives **6a** and **6b**, as shown in Scheme 1. The formation of compound **6b** can be explained by the Claisen rearrangement of the 7-Oallylphenyl ether moiety in **6a** to an O-allylphenol possessing a C-allyl substituent, as shown in Scheme 2. To demonstrate the importance of the presence of phenolic groups for antimicrobial activity, compound **6** was acetylated using acetic anhydride in pyridine at room temperature for 24 h to afford tetraacetylated product **6c** (Scheme 1).



Scheme 1. Synthesis of the semisynthetic derivatives 6a–c.



Scheme 2. Mechanism of the formation of the semisynthetic derivative 6b from 6a.

2.3.1. Characterization of Compounds 6a-c

Compound 6a was obtained as a yellowish finely divided solid soluble in acetone. Its molecular formula was determined to be $C_{34}H_{38}O_6$, with 16 degrees of unsaturation, based on its NMR data and its HRESIMS data, which showed the sodium adduct peak [M + Na]⁺ at m/z 565.2560 (calcd for $C_{34}H_{38}O_6Na^+$: 565.2560). The IR spectrum showed characteristic absorption bands at 3461, 1739.8, 1650, and 1216.5 cm $^{-1}$, indicating the presence of hydroxyl, carbonyl, olefinic double bonds, and ether groups, respectively [35]. The ¹H-NMR spectrum (Table 2) showed the presence of an AA'BB' system with four protons at $\delta_{\rm H}$ 8.18 (H-2'/H-6', J = 9.0 Hz) and 7.12 (d, H-3'/H-5', J = 9.0 Hz); one aromatic singlet at $\delta_{\rm H}$ 6.74 (s, H-6); and a chelated hydroxyl group at 12.87 ppm (OH-5). This spectrum also revealed the presence of three vinylic methyls as singlets at δ_H 1.55 (s, H-8"), 1.60 (s, H-9"), and 1.79 (s, H-10"); three vinylic methylenes at $\delta_{\rm H}$ 3.38 (d, J = 7.2 Hz, H-1"), 1.96 (dd, J = 9.1, 6.3 Hz, H-4"), and 2.05 (m, H-5") together with two olefinic protons at $\delta_{\rm H}$ 5.26 (d, J = 1.5 Hz, H-2") and 5.07 (m, H-6''). These signals were attributable to those of a geranyl group [35]. This was confirmed by HMBC correlations between H-10" (1.79 ppm) and C-3" (122.9 ppm), C-4" (135.5 ppm) and C-5" (40.2 ppm) on one hand, and between H-8" and H-9" and the similar carbons C-6" (125.1 ppm) and C-7" (131.6 ppm) on the other (Figure 2). The 13 C NMR spectrum displayed characteristic signals of a kaempferol derivative at δ_C 138.2 (C-3), 156.0 (C-5), 131.1 (C-2'/C-6'), 115.4 (C-3'/C-5'), and 163.0 (C-7) [36,37]. The HMBC correlation from H-6 (6.74 ppm) and the aromatic carbons at 156.0 (C-5), 163.0 (C-7) and 113.0 (C-8) allowed us to suggest that the geranyl was located at position 8. This was further confirmed by the HMBC correlation between proton H-2" (3.38 ppm) and carbons at 113.0 (C-8), 163.0 (C-7), and 158.6 (C-8a). All of these data were superimposable on those of isomacarangin (6) [36]. Careful examination of the remaining signals of ¹H and ¹³C-NMR spectra together with ¹H–¹H COSY allowed us to identify three allyl groups by the characteristic signals of terminal olefinic methylenes at 118.2/5.30, 117.8/5.50, 117.9/5.52; olefinic methines at 134.8/6.00, 133.8/5.16, 134.2/6.13; and oxymethylene signals at $\delta_{H/C}$ 73.7/4.55, 70.0/4.75, and 69.5/4.69. The linkage of the allyl groups was evidenced by the HMBC correlations depicted from protons at 4.55, 4.75, 4.69 to carbons at 138.2 (C-3), 163.0 (C-7), and 161.6 (C-4'), respectively. According to these spectral data, the structure of **6a** was unambiguously elucidated as 3,7,4'-triallylisomacarangin.

Position —		6a		6b	6с		
	δ _C	$\delta_{\rm H}$ (m, J in Hz)	δ _C	δ_{H} (m, J in Hz)	δ _C	δ_{H} (m, J in Hz)	
2	156.7		158.3		154.3		
3	138.2		138.2		134.6		
4	179.3		178.7		170.5		
4a	106.4		108.7		115.4		
5	156.0		157.3		149.0		
6	91.7	6.74 <i>,</i> s	112.3		111.7	8.31, s	
7	163.0		162.1		155.2		
8	113.0		112.3		126.4		
8a	158.6		153.2		155.6		
1'	123.9		124.0		127.9		
2'/6'	131.1	8.13 (d, 9.0)	131.3	8.17 (d, 9.0)	130.6	8.81 (d, 8.8)	
3'/5'	115.4	7.12 (d, 9.0)	115.6	7.14 (d, 9.0)	123.2	8.16 (d, 8.8)	
4'	161.6		161.8		154.2		
1''	22.0	3.38 (d, 7.2)	23.1	3.41 (d, 6.8)	23.8	4.13, brs	
2''	122.9	5.26 (d, 1.5)	123.5	5.28, m	121.6	5.83, s	
3''	135.5		135.8		136.9		
4''	40.2	1.96 (dd, 9.0; 6.3)	39.6	1.93 (t, 7.3)	40.3	2.76/2.84, m	
5''	27.3	2.05, m	27.2	2.05, s	27.2	2.83, m	
6''	125.1	5.05, m	125.0	5.06, m	124.9	5.86, m	
7''	131.6		131.7		131.8		
8′′	17.8	1.55, s	17.4	1.54, s	17.7	2.58, s	
9''	25.7	1.60, s	25.8	1.59, s	25.7	2.42, s	
10''	16.3	1.79, s	16.4	1.77, s	16.4	2.36, s	
Allyl							
3-O-Allyl	73.7	4.55 (d, 6.0)	73.7	4.75 (d, 6.0)			
	134.8	6.00, m	134.8	5.90, m			
	118.2	5.30, m	118.4	5.16, m			
7-0-Allyl	70.0	4.75, (d, 6.0)	76.1	4.45, (d, 6.0)			
	133.8	5.16, m	134.7	5.90, m			
	117.8	5.50, m	117.4	5.26, m			
4'-O-Allyl	69.5	4.69, (d, 6.0)	69.5	4.70, (d, 6.0)			
	134.2	6.13 <i>,</i> m	134.2	6.12, m			
	117.9	5.52, m	117.9	5.17, m			
6-C-Allyl			28.5	3.54, m			
			137.3	6.05, m			
أحجاجا			115./	7.14, m			
Acetyl					20.4	0.01	
3-AC					20.4	2.31, S	
5 4 2					109.4	2.22	
5-AC					21.1 169.2	2.32, 8	
7 4 -					100.3	2 20 -	
7-AC					20.4 160 2	2.39, 8	
11 10					109.2 21.0	2 40 0	
4 -AC					∠1.0 168 /	∠.40, S	
					100.4		

Table 2. ¹³C and ¹H-NMR spectroscopic data of compounds **6a–c** (¹H 500 MHz, ¹³C 125 MHz in acetone $-d_6$).



Figure 2. Keys ${}^{1}H-{}^{1}H$ COSY and HMBC correlations of compounds 6a and 6b.

Compound **6b** was also obtained as a yellowish finely divided solid soluble in acetone. Its molecular formula was determined to be $C_{37}H_{42}O_6$, with 17 double bond equivalents, on the basis of its NMR data and its HRESIMS data, which showed the protonated adduct peak $[M + Na]^+$ at m/z 583.3052 (calcd m/z 583.3054 for $C_{37}H_{43}O_6^+$). The ¹H NMR spectrum of **6b** was closely related to that of **6a** (see Table 2) with the exception of the disappearance of the aromatic signal at 6.74 ppm on the A ring in **6a**, indicating a substitution at this position. Extensive analysis of the proton spectrum showed the presence of additional signals at δ_H 3.64, 6.05, and 7.14 ppm, which correlated in the HSQC with carbons at δ_C 28.5, 137.3, and 115.7 ppm, respectively, and indicated the presence of one C-allyl group in **6b**, which was further confirmed by the combined DEPT 135 and ¹H–¹H COSY (Figure 2) spectra. The linkage of the additional allyl group was evidenced by the HMBC correlation between the proton at δ_H 3.54 ppm and C-6 (112.3 ppm), C-5 (157.3) and C-7 (162.1). Consequently, compound **6b** was elucidated as 3,6,7,4'-tetraallylisomacarangin.

Compound **6c** was isolated as a yellowish finely divided solid soluble in acetone. Its NMR data in association with its HRESIMS showed the sodium adduct peak [M + Na]⁺ at m/z 613.2043 (calcd for $C_{33}H_{34}O_{10}Na^+$, 613.2044), which led to the assignment of $C_{33}H_{34}O_{10}$, with 17 double bond equivalents, as the molecular formula of **6c**. The ¹H-NMR spectrum (Table 1) of **6c** was closely related to those of isomacarangin (**6**) [35,36] with the signals of the AA'BB' system of four protons at δ_H 8.81 (H-2'/H-6', J = 8.8 Hz) and 8.16 (d, H-3'/H-5', J = 8.8 Hz) and one aromatic singlet at δ_H 8.31 (s, H-6) and the characteristic signals of the geranyl group [35]. Extensive analysis of its ¹H-NMR spectrum displayed the signals of four methyl protons at δ_H 2.31, 2.32, 2.39, and 2.40 ppm, which correlated in the HSQC spectrum with carbons at δ_C 20.4, 21.1, 20.4, and 21.0 ppm. The ¹³C-NMR spectrum of **6c** displayed four additional carbonyl signals at δ_C 169.4, 168.3, 169.2, and 168.4 ppm, indicating the presence of four acetyl units located in the four previously hydroxylated aromatic positions of isomacarangin (**6**). Therefore, compound **6c** was elucidated as 3,5,7,4'-tetraacetylisomacarangin.

2.3.2. Antimicrobial Activity of Compounds 6a–c

The semisynthetic derivatives obtained (**6a–c**) were screened against all the selected strains, and the results obtained reveal that all the semisynthetic compounds were less active (MIC >500 μ g/mL) than isomacarangin (**6**) (MIC = 500 μ g/mL). These results further confirmed the effect of the hydroxyl groups of flavonoids on the antibacterial activity against bacterial growth (Table 2).

2.4. Chemical Significance of the Isolated Compounds

The present study reports the first chemical investigation of *M. occidentalis*. To the best of our knowledge, this is the first report on the isolation of the specialized metabolites of *M. occidentalis*. However, some of the isolated compounds were reported from other species of the studied genus. This is the case for β -sitosterol (1), stigmasterol (2), and β -sitosterol-3-O- β -D-glucopyranoside (3) isolated from *M. magna* [14]; lupeol (4), evidenced from *M. balansae* [16]; schweinfurthins O and B (9 and 10), previously found in *M. tanarius*, and M. schweinfurthii [8,19]. Isomacarangin (6) was found in M. barteri [6] and M. schwein*furthii* [36]; kaempferol (7) and quercetin (8) were isolated from *M. indica* [18]; ellagic acid (11) was found in *M. barteri* [11]. Nevertheless, this work reports, for the first time, the isolation of the glycosylated flavonoid apigenin-7-O- β -D-glycoside (5) from the Macaranga genus. However, this compound has already been isolated from other genera of the Euphorbiaceae family including *Euphorbia humifusa* [17] and *Chrozophora rottleri* [38]. Among the ellagic acid derivatives isolated from this plant, 3,4-methylenedioxy-3'-O-methylellagic (12), 3,3',4tri-O-methylellagic acid 4'-O- β -D-glucopyranoside (**13**), and 3,3',4'-tri-O-methylellagic acid (14) were isolated for the first time in the Euphorbiaceae family. Furthermore, the presence of ellagic acid derivatives in the *Maracanga* genus was already reported by Mgoumfo et al. (2008) [11]. This work also reports the first isolation of the geraniinic acid derivative, (5R,6R)-4,6-dihydrocarbonyl-5-[2',3',4'-trihydroxy-6'-(methoxycarbonyl)phenyl]-5,6dihydro-2H-pyran-2-one (15), and coumarin methyl brocchllin carboxylate (16) from the Macaranga genus. Furthermore, these two secondary metabolites have been isolated from Phyllanthus reticulatus and Chrozophora brocchiana, respectively, which belong to the Euphorbiaceae [23,24]. Nevertheless, the isolation of a coumarin from this plant is not surprising since two coumarins have previously been isolated from many Macaranga species such as *M. barteri* [11], *M. gigantifolia* [10], and *M. triloba* [39]. In addition, the isolated coumarin is a structural analog of the methyl brevifolin carboxylate previously isolated from *M. tanarius* [40]. This evidence suggests that there is a relationship between the genera Macaranga, Phyllanthus, and Chrozophora within the Euphorbiaceae family. We herein present the first isolation of ishigoside (17) in the Euphorbiaceae. This compound, which was isolated for the first time from the brown alga Ishige okamurae (Ishigeaceae) [25], was recently isolated from the terrestrial plant Dracaena stedneuri (Dracaenaceae) [41], thus, its presence in *M. occidentalis* is not surprising. Being cognizant of the fact that prenylated flavonoids and stilbenes constitute the chemotaxonomic markers of the *Macaranga* genus [5], these chemical findings confirm the botanical identification of M. occidentalis and further indicate a close relationship with other species of this genus. Additionally, ellagic acid derivatives, which constitute one of the main classes of secondary metabolites isolated from this plant, could then be considered as a chemotaxonomic marker of this species. The anthelmintic potential of schweinfurthins O and B (9 and 10) could be investigated as similar compounds (grifolin and geranyl-2-orcinol) showed anthelmintic activity against *C. elegans* and newly transformed schistosomules [42].

3. Materials and Methods

3.1. General

Electrospray ionization (ESI) mass spectra were recorded on a 1200-series HPLC system or a 1260-series Infinity II HPLC-system (Agilent Technologies, Santa Clara, CA, USA) with a binary pump and integrated diode array detector coupled to an LC/MSDTrap-XTC-mass spectrometer (Agilent Technologies) or an LC/MSD Infinity Lab LC/MSD (G6125B LC/MSD). High-resolution mass spectra were recorded on a Micromass-Q-TOFUltima-3-mass spectrometer (Waters, Milford, MA, USA) with a Lock Spray-interface and a suitable external calibrant. UV—Vis spectra were recorded on an Evolution 201 UV—Visible Spectrophotometer (Thermo Scientific, Waltham, MA, USA), and infrared (IR) spectra were recorded on a Tensor 27 FTIR-spectrometer (Bruker, Billerica, MA, USA) equipped with a diamond ATR. 1D and 2D-NMR spectra were obtained on a Bruker Avance III 500 HD or Avance 600. (Bruker, Bremen, Germany), and TMS was used as an internal standard. Column chromatography was carried out on silica gel 230–400 mesh and silica gel 70–230 mesh (Merck, Darmstadt, Germany). Thin-layer chromatography (TLC) was performed on Merck precoated silica gel 60 F₂₅₄ aluminum foil and revealed using a UV lamp (254–365 nm) and 10% H₂SO₄ reagent, followed by heating.

3.2. Plant Material

The leaves of *M. occidentalis* were collected at Batoufam village (5°16′42

//

north, 10°27′57

east) near Bandjoun in the Koung-Khi Subdivision, West Region of Cameroon in 2017. Specimens of the collection were deposited at the Cameroon National Herbarium in Yaoundé (Ref no. 50436/NHC).

11

3.3. Extraction and Isolation

The air-dried and powdered leaves of *M. occidentalis* (3.0 kg) were extracted with DCM-MeOH (15 L, 1:1, v/v, 3 × 24 h) at room temperature, and the filtrate obtained was

evaporated under vacuum at 45 °C to yield the crude DCM-MeOH extract (203.7 g). Part of the extract (200 g) was suspended in distilled water (600 mL) and successively partitioned with EtOAc and n-BuOH (1 L each) to give 76.8 g and 48.5 g of fractions, respectively. Part of the EtOAc fraction (70 g) was subjected to silica gel column chromatography (CC) using gradient elution with the mixture n-hexane/acetone as the mobile phase in a stepgradient from 9:1 to 1:9 (v/v) and acetone–MeOH (10:0 to 4:1, v/v) to afford four major subfractions (Fr. A–Fr. D). Fr. A (8.5 g) was fractionated by n-hexane–acetone (19:1 to 9:1, v/v) on normal-phase CC to give two main subfractions Fr. A.1-Fr. A.2. Lupeol (4; 15.2 mg), β -sitosterol, and stigmasterol (1 + 2; 25.8 mg) were obtained after the filtration of Fr. A.1 (1.28 g) and Fr. A.2 (3.5 g), respectively. CC of Fr. B (11.6 g) eluted with n-hexane–acetone (17:3, v/v) afforded two main subfractions Fr. B.1 (3.2 g) and Fr. B.2 (5.3 g). CC over silica gel of Fr. B.1 eluted with n-hexane–acetone (9:1 to 17:3, v/v) led to the isolation of 3',4'-methylenedioxy-3-O-methylellagic (12; 6.9 mg) and 3,3',4'-tri-Omethyl ellagic acid (14; 3.3 mg). Fr. B.2 was subjected to CC over silica gel eluted with n-hexane–acetone (4:1, v/v) to afford kaempferol (7; 6.2 mg) and quercetin (8; 8.1 mg). Fr C (17.8 g) was subjected to CC over Sephadex LH-20 and eluted with DCM–MeOH (1:4, v/v) to yield (5R,6R)-4,6-dihydrocarbonyl-5-[2',3',4'-trihydroxy-6'-(methoxycarbonyl)phenyl]-5,6-dihydro-2H-pyran-2-one (15; 4.5 mg) and isomacarangin (6; 57.9 mg). Fr. D (21 g) was separated by CC over silica gel, and eluted with an isocratic system n-hexane–acetone (3:2, v/v) to give two main subfractions Fr. D.1 (3.7 g) and Fr. D.2 (4.2 g). Fr. D.1 was repeatedly chromatographed on silica gel with n-hexane–acetone (3:1, v/v) to afford schweinfurthin O (9; 3.5 mg) and schweinfurthin B (10; 25.3 mg). The Sephadex LH-20 CC of Fr D.2 (17.8 g) eluted with MeOH afforded methyl brocchllin carboxylate (16; 7.5 mg). The n-BuOH soluble fraction (40 g) was subjected to CC over silica gel eluted with acetone–MeOH (1:0 to 1:1, v/v) to give two major fractions Fr. E (12 g) and Fr. F (8.3 g). Fr. E was subjected to CC eluted with the ternary system EtOAc–MeOH–H₂O (9:1:0.5, v/v/v) on normal phase CC to give three subfractions Fr. E. 1–Fr. E.3. Subfraction Fr. E.1 (1.1 g) was subjected to repeated CC eluted with EtOAc–MeOH–H₂O (95:5:2, v/v/v) to afford ishigoside (17; 5.2 mg). β -Sitosterol 3-O- β -D-glucopyranoside (3; 12 mg) precipitated from subfraction Fr. E.2 (2.2 g). Fr. E.3 (1.5 g) was subjected to CC eluted with EtOAc–MeOH–H₂O (9:1:0.5, v/v/v) to afford 3,3',4-tri-O-methylellagic acid 4'-O- β -D-glucopyranoside (**13**; 8.2 mg). Silica gel CC of Fr. F eluted with the ternary system EtOAc–MeOH– H_2O (9:1:0.5, v/v/v) on normal phase gave two subfractions Fr. F. 1 (2.3 g) and Fr. F.2 (1.7 g). Sephadex LH-20 CC of Fr. F.1 eluted with MeOH afforded ellagic acid (11; 9.7 mg). CC of Fr.F.2 eluted with EtOAc-MeOH–H₂O (9:0.7:0.3, v/v/v) afforded apigenin-7-O-β-D-glycopyranoside (5; 4.6 mg). A simplified scheme describing the extraction, fractionation, and isolation of compounds 1–17 is presented in the Supplementary Materials (Scheme S1).

3.4. Spectroscopic Data of the Isolated Compounds

β-Sitosterol (1): white powder; ¹H-NMR (500 MHz, CDCl₃): $\delta_{\rm H}$ (mult, *J* in Hertz): 5.34 (m, H-6), 3.52 (m, H-3), 1.01 (s, H-27), 0.92 (d, *J* = 6.5 Hz, H-19, H-21), 0.84 (d, *J* = 2.9 Hz, H-29), 0.83 (d, *J* = 2.2 Hz, H-26), 0.68 (s, H-18); ¹³C NMR (125 MHz, CDCl₃): $\delta_{\rm C}$ 140.8 (C-5), 121.8 (C-6), 71.9 (C-3), 56.9 (C-14), 56.2 (C-17), 50.2 (C-9), 45.9 (C-24), 42.7 (C-13), 42.4 (C-4), 39.9 (C-12), 37.4 (C-1), 36.6 (C-10), 36.2 (C-20), 34.0 (C-22), 32.1 (C-7), 32.0 (C-8), 31.8 (C-2), 29.2 (C-25), 28.4 (C-16), 26.2 (C-23), 24.4 (C-15), 23.2 (C-28), 21.2 (C-11), 19.9 (C-26), 19.5 (C-27), 19.1 (C-19), 18.9 (C-21), 12.1 (C-18), 12.0 (C-29).

Stigmasterol (2): white powder; ¹H-NMR (500 MHz, CDCl₃): $\delta_{\rm H}$ (mult, *J* in Hertz): 5.34 (m, H-6), 5.15 (dd, *J* = 15.1, 8.7 Hz, H-22), 5.01 (dd, *J* = 15.1, 8.7 Hz, H-23), 3.52 (m, H-3), 1.25 (brs, H-19), 1.01 (s, H-27), 0.94 (brs, H-21), 0.84 (d, *J* = 2.9 Hz, H-29), 0.81 (s, H-24), 0.70 (s, H-18; ¹³C NMR (125 MHz, CDCl₃): $\delta_{\rm C}$ 140.8 (C-5), 138.4 (C-22), 129.1 (C-23), 121.8 (C-6), 71.5 (C-3), 57.0 (C-14), 56.1 (C-17), 51.3 (C-9), 45.3 (C-24), 42.7 (C-13), 42.3 (C-4), 40.6 (C-20), 39.8 (C-12), 37.1 (C-1), 36.0 (C-10), 32.7 (C-7), 32.2 (C-8), 31.6 (C-2), 29.0 (C-25), 28.8 (C-16), 25.5 (C-28), 24.5 (C-15), 21.3 (C-11), 20.8 (C-21), 18.8 (C-26), 18.4 (C-27), 17.7 (C-19), 12.4 (C-18), 12.2 (C-29).

β-Sitosterol-3-*O*-β-D-glucopyranoside (**3**): white powder; ¹H NMR (500 MHz, C₅D₅N, 25 °C, TMS): 5.34 (brs, 1H, H-6), 5.03 (d, *J* = 7.5 Hz, 1H, H-1'), 4.56 (dd, *J* = 11.9, 2.6 Hz, 2H, H-6'), 4.28 (m, H-4', H-5'), 4.05 (t, 8.1 Hz, H-2'), 3.96 (m, H-3, H-3'), 1.42 (m, H-27), 1.28 (br s, H-28), 0.97 (d, *J* = 6.3 Hz, H-20, H-24, H-26), 0.92 (s, H-19), 0.87 (br s, H-29), 0.84 (br s, H-21); ¹³C NMR (125 MHz, C₅H₅N): $\delta_{\rm C}$ 37.6 (C-1), 30.4 (C-2), 78.8 (C-3), 40.1 (C-4), 141.1 (C-5), 122.1 (C-6), 32.2 (C-7), 32.3 (C-8), 50.5 (C-9), 37.1 (C-10), 21.4 (C-11), 39.5 (C-12), 42.6 (C-13), 56.4 (C-14), 24.7 (C-15), 28.6 (C-16), 57.0 (C-17), 12.3 (C-18), 19.6 (C-19), 36.5 (C-20), 19.4 (C-21), 34.4 (C-22), 26.5 (C-23), 46.2 (C-24), 29.6 (C-25), 19.2 (C-26), 20.1 (C-27), 23.5 (C-28), 12.1 (C-29), 102.7 (C-1'), 75.5 (C-2'), 78.6 (C-3'), 71.8 (C-4'), 78.3 (C-5'), 63.0 (C-6').

Lupeol (4): ¹H NMR (500 MHz, CDCl₃, 25 °C, TMS): δ = 4.69 (d, *J* = 2.4 Hz, 1H, H-29b), 4.56 (d, *J* = 2.7 Hz, 1H, H-29a), 3.18 (dd, *J* = 11.4, 4.9 Hz, 1H, H-3), 1.68 (s, 3H, H-30), 1.03 (s, 3H, H-26), 0.97 (s, 3H, H-23), 0.94 (s, 3H, H-27), 0.83 (s, 3H, H-25), 0.79 (s, 3H, H-28). ¹³C NMR (125 MHz, CDCl₃): 38.8 (C-1), 27.3 (C-2), 79.1 (C-3), 39.0 (C-4), 55.4 (C-5), 18.4 (C-6), 34.3 (C-7), 40.9 (C-8), 50.6 (C-9), 37.3 (C-10), 21.0 (C-11), 25.2 (C-12), 38.2 (C-13), 42.9 (C-14), 27.5 (C-15), 35.7 (C-16), 43.1 (C-17), 48.4 (C-18), 48.1 (C-19), 151.0 (C-20), 29.9 (C-21), 40.1 (C-22), 28.0 (C-23), 14.7 (C-24), 16.2 (C-25), 16.1 (C-26), 15.5 (C-27), 18.1 (C-28), $\delta_{\rm C}$ 109.4 (C-29), 19.4 (C-30).

Apigenin-7-*O*-*β*-D-glycoside (5): ¹H NMR (500 MHz, C₅D₅N, 25 °C, TMS): δ = 13.60 (d, *J* = 4.2 Hz, 1H), 6.90 (brs,1H, H-3), 6.84 (brs, 1H, H-6), 7.09 (brs, 1H, H-8), 7.90 (d, *J* = 8.7 Hz, 2H, H-2'/H-6'), 7.17 (d, *J* = 8.7 Hz, 2H, H-3'/H-5'), 5.84 (d, *J* = 5.6 Hz, 1H, H-1"), 4.35 (dd, *J* = 5.6, 9.5 Hz 1H, H-2"), 4.22 (m, 1H, H-3"), 4.35 (m, 1H, H-4"), 4.56/4.37(d, *J* = 11.9 Hz, 2H, H-6_{a,b}"), 4.40 (m, 1H, H-5").—¹³C NMR (125 MHz, C₅D₅N): δ = 165.4 (C-2), 104.4 (C-3), 183.4 (C-4), 163.0 (C-5), 101.2 (C-6), 164.5 (C-7), 95.7(C-8), 158.2 (C-8a), 107.0 (C-4a), 122.4 (C-1'), 129.5(C-2'/C-6'), 117.4 (C-3'/C-5'), 163.3 (C-4'), 102.1 (C-1"), 75.2 (C-2"), 78.8 (C-3"), 71.5 (C-4"), 79.7(C-5"), 62.7(C-6").

Isomacarangin (6): ¹H NMR (500 MHz, CD₃OD, 25 °C, TMS): $\delta = 6.21$ (s, 1H, H-6), 8.08 (d, J = 8.9 Hz, 2H, H-2'/H-6'), 6.86 (d, J = 8.9 Hz, 2H, H-3'/H-5'), 3.48 (d, J = 6.8 Hz, 2H, H-1"), 5.19 (m, 1H, H-2"), 1.94 (t, J = 7.3 Hz, 2H, H-4"), 2.00 (t, J = 7.3 Hz, 2H, H-5"), 4.96 (m, 1H, H-6"), 1.77 (s, 3H, H-8"), 1.49 (d, J = 1.5 Hz, 3H, H-9"), 1.44 (s, 3H, H-10")—¹³C NMR (125 MHz, CD₃OD) $\delta = 147.8$ (C-2), 136.8 (C-3), 177.4 (C-4), 155.4 (C-5), 98.5 (C-6), 162.5 (C-7), 107.5 (C-8), 159.9 (C-8a), 104.3 (C-4a), 123.9 (C-1'), 130.6 (C-2'), 116.1 (C-3'), 160.4 (C-4'), 116.1 (C-5'), 130.6 (C-6'), 22.2 (C-1"), 123.9 (C-2"), 135.9 (C-3"), 40.5 (C-4"), 27.4 (C-5"), 125.1 (C-6"), 132.0 (C-7"), 16.4 (C-8"), 25.6 (C-9"), 17.3 (C-10").

Kaempferol (7): ¹H NMR (500 MHz, acetone- d_6 , 25 °C, TMS): $\delta = 6.55$ (d, J = 1.8 Hz, 1H, H-6), 6.29 (d, J = 1.8 Hz, 1H, H-8), 7.03 (d, J = 8.8 Hz, 2H, H-2'/H-6'), 8.17 (d, J = 8.8 Hz, 2H, H-3'/H-5'). ¹³C NMR (125 MHz, acetone- d_6) $\delta = 146.1$ (C-2), 137.0 (C-3), 156.9 (C-5), 93.6 (C-6), 164.2 (C-7), 98.3 (C-8), 161.6 (C-8a), 103.5 (C-4a), 122.9 (C-1'), 129.5 (C-2'/C-6'), 115.4 (C-3'/C-5'), 159.2 (C-4').

Quercetin (8): ¹H NMR (500 MHz, DMSO– d_6 , 25 °C, TMS): δ = 6.52 (d, *J* = 1.9 Hz, 1H, H-6), 6.26 (d, *J* = 1.9 Hz, 1H, H-8), 6.99 (d, *J* = 8.5 Hz, 1H, H-2'), 7.82 (d, *J* = 2.1 Hz, 1H, H-5'), 7.69 (dd, *J* = 8.5, 2.1 Hz, 1H, H-6').—¹³C NMR (125 MHz, DMSO– d_6) δ = 146.8 (C-2), 136.6 (C-3), 176.4 (C-4), 157.7 (C-5), 94.4 (C-6), 162.3 (C-7), 99.0 (C-8), 162.0 (C-8a), 104.1 (C-4a), 123.7 (C-1'), 116.1 (C-2'), 145.7 (C-3'), 148.2 (C-4'), 115.6 (C-5'), 121.4 (C-6').

Schweinfurthin O (9): ¹H NMR (500 MHz, acetone- d_6 , 25 °C, TMS): δ = 7.03 (d, J = 2.0 Hz, 1H, H-3), 6.87 (d, J = 2.0 Hz, 1H, H-5), 6.80 (s, 1H, H-6), 6.81 (d, J = 16.2 Hz, 1H, H-1'), 6.76 (d, J = 16.2 Hz, 1H, H-2'), 6.57 (s, 1H, H-4'), 6.57 (s, 1H, H-8'), 3.37 (d, J = 7.1 Hz, 2H, H-1"), 5.33 (tq, J = 7.2, 1.4 Hz, 1H, H-2"), 1.79 (d, J = 1.3 Hz, 3H, H-4"), 1.98 (s, 1H, H-5"), 2.06 (d, J = 1.3 Hz, 2H, H-6"), 5.12 (ddt, J = 7.1, 4.0, 1.4 Hz, 1H, H-7"), 1.57 (s, 3H, H-9"), 1.95 (s, 1H, H-10"), 2.02 (d, J = 7.1 Hz, 2H, H-11"), 5.08 (m, 1H, H-12"), 1.57 (s, 3H, H-14"), 1.63 (dd, J = 5.2, 1.4 Hz, 3H, H-15")—¹³C NMR (125 MHz, acetone- d_6) δ = 146.2 (C-1), 145.0 (C-2), 113.7 (C-3), 136.3 (C-4), 119.9 (C-5), 116.3 (C-6), 128.4 (C-1'), 127.0 (C-2'), 130.9 (C-3'), 105.7 (C-4'), 156.1 (C-5'), 115.3 (C-6'), 156.9 (C-7'), 105.7 (C-8'), 23.2 (C-1"), 124.3 (C-2"), 134.6 (C-3"), 16.3 (C-4"), 40.6 (C-5"), 27.4 (C-6"), 125.1 (C-7"), 134.3 (C-8"), 16.1 (C-9"), 40.5 (C-10"), 27.5 (C-11"), 125.3 (C-12"), 131.6 (C-13"), 17.7 (C-14"), 25.9 (C-15").

Schweinfurthin B (10): $[\alpha]_D = +44.5^{\circ}$ (c 1.0, EtOH); ¹H NMR (500 MHz, acetone- d_6 , 25 °C, TMS): $\delta = 3.30$ (d, J = 3.5 Hz, 1H, H-2), 4.13(m, 1H, H-3), 2.29/1.91 (dd, J = 13.9, 3.1 Hz, 2H, H-4_{a,b}), 6.92 (d, J = 1.9 Hz, 1H, H-6), 6.81 (d, J = 1.9 Hz, 1H, H-8), 2.75 (m, 2H, H-9), 1.68 (dd, J = 12.7, 5.3 Hz, 1H, H-9a), 1.05 (s, 6H, H-11/H-12), 1.36 (s, 3H, H-13), 6.88 (m, 2H, H-1'/H-2'), 6.57 (s, 2H, H-4'/H-8'), 3.35 (d, J = 7.1 Hz, 2H, H-1"), 5.30 (m, 1H, H-2"), 1.75 (d, J = 1.4 Hz, 3H, H-4"), 1.91 (d, J = 7.2 Hz, 2H, H-5"), 2.05 (s, 1H, H-6"), 5.05 (m, 1H, H-7"), 1.52 (d, J = 1.3 Hz, 3H, H-9"), 1.58 (d, J = 1.5 Hz, 3H, H-10"), 3.75 (s, 3H, 5-OCH₃).—¹³C NMR (125 MHz, acetone- d_6) $\delta = 38.3$ (C-1), 77.6 (C-2), 71.3 (C-3), 44.0 (C-4), 76.8 (C-4a), 149.7 (C-5), 107.9 (C-6), 129.8 (C-7), 121.0 (C-8), 123.4 (C-8a), 22.7 (C-9), 47.5 (C-9a), 143.1 (C-10a), 16.1 (C-11), 28.9 (C-12), 21.7 (C-13), 128.1 (C-1'), 126.7 (C-2'), 136.9 (C-3'), 105.4 (C-4'/C-8'), 156.6 (C-5'), 114.8 (C-6'), 156.6 (C-7'), 23.3 (C-1"), 123.7 (C-2"), 134.1 (C-3"), 15.9 (C-4"), 40.2 (C-5"), 27.1 (C-6"), 124.8 (C-7"), 136.1 (C-8"), 17.3 (C-9"), 25.5 (C-10"), 55.7 (5-OCH₃).

Ellagic acid (**11**): ¹H NMR (500 MHz, DMSO- d_6 , 25 °C, TMS): δ = 7.81 (s, 2H, H-2/H-2')—¹³C NMR (125 MHz, DMSO- d_6) δ = 108.6 (C-1/C-1'), 111.5 (C-2/C-2'), 149.6 (C-3/C-3'), 145.1 (C-4/C-4'), 137.7 (C-5/C-5'), 113.6 (C-6/C-6'), 160.6 (C-7/C-7').

3',4'-Methylenedioxy-3-O-methylellagic (12): ¹H NMR (500 MHz, DMSO- d_6 , 25 °C, TMS): δ = 7.56 (s, 1H, H-5), 7.55 (s, 1H, H-5'), 4.06 (s, 3H, 3-OCH₃), 6.40 (s, 2H, -OCH₂-).— ¹³C NMR (125 MHz, DMSO- d_6) δ = 112.7 (C-1), 131.1 (C-2), 140.2 (C-3), 152.7 (C-4), 112.0 (C-5), 116.1 (C-6), 157.7 (C-7), 111.2 (C-1'), 141.6 (C-2'), 138.3 (C-3'), 150.0 (C-4'), 103.9 (C-5'), 111.0 (C-6'), 158.3 (C-7'), 61.0 (3-OMe), 104.1 (-OCH₂O-).

3,3',4-Tri-O-methylellagic acid 4'-O-β-D-glucopyranoside (13): ¹H NMR (500 MHz, C₅D₅N, 25 °C, TMS): δ = 7.85 (d, *J* = 1.7 Hz, 1H, H-5) 8.49 (d, *J* = 1.7 Hz, 1H, H-5'), 5.94 (d, *J* = 5.6 Hz, 1H, H-1'), 4.45 (s, 1H, H-2'), 4.44 (s, 1H, H-3'), 4.42 (d, *J* = 1.7 Hz, 1H, H-4'), 4.21 (d, *J* = 1.9 Hz, 1H, H-5'), 4.62 (d, *J* = 12.1 Hz, 1H, H-6'), 4.17 (d, *J* = 1.7 Hz, 3H, 3-OCH₃), 3.89 (d, *J* = 1.7 Hz, 3H, 4-OCH₃), 4.30 (d, *J* = 1.7 Hz, 3H, 3'-OCH₃).—¹³C NMR (125 MHz, C₅D₅N): δ = 113.7 (C-1), 142.5(C-2), 142.4 (C-3), 155.5 (C-4), 108.5 (C-5), 114.6 (C-6), 159.3 (C-7), 114.0 (C-1'), 143.3 (C-2'), 142.5 (C-3'), 153.5 (C-4'), 113.8 (C-5'), 113.9 (C-6'), 159.5 (C-7'), 103.4 (C-1''), 75.3 (C-2''), 79.0 (C-3''), 71.5 (C-4''), 79.6 (C-5''), 62.8 (C-6''), 62.0 (3-OCH₃), 57.1(4-O CH₃), 62.4 (3'-OCH₃).

3,3',4'-Tri-O-methyl ellagic acid (14): ¹H NMR (500 MHz, C₅D₅N, 25 °C, TMS): $\delta = 8.08$ (s, 1H, H-5), 7.86 (s, 1H, H-5'), 4.17 (s, 3H, 3-OCH₃), 4.23 (s, 3H, 3'-OCH₃), 3.88 (s, 3H, 4'-OCH₃).—¹³C NMR (125 MHz, C₅D₅N) $\delta = 114.1$ (C-1), 142.1 (C-2), 141.9 (C-3), 154.7 (C-4), 108.2 (C-5), 113.2 (C-6), 159.5 (C-7), 113.5 (C-1'), 142.5 (C-2'), 141.5 (C-3'), 154.5 (C-4'), 113.1 (C-5'), 112.0 (C-6'), 159.5 (C-7'), 61.7 (3-OCH₃), 61.5 (3'-OCH₃), 56.8 (4'-OCH₃).

(5R,6R)-4,6-Dihydrocarbonyl-5-[2',3',4'-trihydroxy-6'(methoxycarbonyl)phenyl]-5, 6-dihydro-2H-pyran-2-one (**15**): $[\alpha]_D = +171.2^{\circ}$ (c 0.5, acetone); ¹H NMR (500 MHz, CD₃OD, 25 °C, TMS): $\delta = 6.85$ (s, 1H, H-3), 5.38 (d, *J* = 1.9 Hz, 1H, H-5), 5.32 (d, *J* = 1.9 Hz, 1H, H-6), 7.06 (br s, 1H, H-5'), 3.66 (s, 3H, 4-CH₃), 3.71 (s, 3H, 6-CH₃), 3.66 (s, 3H, 6'-CH₃).—¹³C NMR (125 MHz, CD₃OD): $\delta = 166.9$ (C-2), 130.3 (C-3), 143.1 (C-4), 35.7 (C-5), 80.3 (C-6), 117.1 (C-1'), 144.3 (C-2'), 140.5 (C-3'), 147.0 (C-4'), 108.8 (C-5'), 116.3 (C-6'), 167.8 (1"-C=O), 53.5 (1"-OCH₃), 171.1 (2"-C=O), 52.7 (2"-OCH₃), 165.4 (3"-C=O), 53.1 (3"-OCH₃).

Methylbrocchllin carboxylate (16): ¹H NMR (500 MHz, CD₃OD, 25 °C, TMS): $\delta = 2.89/2.41$ (dd, J = 18.7, 7.7 Hz, 1H, H-2_{a.b}), 4.35 (dd, J = 7.7, 2.1 Hz, 1H, H-3), 7.22 (s, 1H, H-6), 3.54 (s, 3H, OCH₃).—¹³C NMR (125 MHz, CD₃OD): $\delta = 202.7$ (C-1), 46.6 (C-2), 50.2 (C-3), 155.5 (C-3a), 169.5 (C-5), 122.7 (C-5a), 117.8 (C-6), 159.3 (C-7), 150.0 (C-8), 153.2 (C-9), 124.7 (C-9a), 148.1 (C-3b), 182.2 (3-C=O), 61.7 (OCH₃).

Ishigoside (17): ¹H NMR (500 MHz, CDCl₃/CD₃OD, 25 °C, TMS): $\delta = 4.20/3.70$ (d, J = 5.3 Hz, 2H, H-1_{a,b}), 5.44 (m, 1H, H-2), 4.61/4.30 (dd, J = 12.1, 3.0 Hz, 2H, H-3_{a,b}), 4.90 (d, J = 3.8 Hz, 1H, H-1'), 3.55 (dd, J = 9.7, 3.8 Hz, 1H, H-2'), 3.76 (t, J = 9.3 Hz, 1H, H-3'), 3.28 (t, J = 9.4 Hz, 1H, H-4'), 4.17 (d, J = 2.0 Hz, 1H, H-5'), 3.46/3.10 (dd, J = 14.4, 8.6 Hz 1H, H-6'_{a,b}), 2.45 (m, 4H, H-2''/H-2 '''), 1.38 (s, 24H, H-3''-H-14'', H-3 '''-H-14 '''), 1.71 (m, 4H, H-15''/H-15 '''), 0.99 (t, J = 7.0 Hz, 6H, H-16''/H-16 ''').—¹³C NMR (125 MHz, CDCl₃/CD₃OD) $\delta = 66.7$ (C-1), 71.2 (C-2), 63.9 (C-3), 99.5 (C-1'), 72.8 (C-2'), 74.4 (C-3'), 74.3

(C-4'), 69.3 (C-5'), 53.8 (C-6'), 175.0 (C-1"), 34.9 (C-2"), 32.6–29.8 (C-3"-C-14"), 25.6 (C-15"), 174.8 (C-1"'), 34.8 (C-2"'), 32.6–29.8 (C-3"'-C-14"'), 23.6 (C-15"'), 14.7 (C-16"/C-16"').

3.5. Preparation of the Semisynthetic Derivatives

3.5.1. Allylation of Isomacarangin (6)

Isomacangin (6) (25.1 mg, 0.059 mmol) was dissolved in 3 mL of acetone; allyl bromide (3 mL) and K₂CO₃ (5 mg, 0.036 mmol) were added successively. The mixture was magnetically stirred at 25 °C and monitored by TLC until the disappearance of the starting material [43]. After 24 h of reaction, it was poured into ice (100 g) and extracted with EtOAc (3 × 10 mL). The organic layer was washed with water (3 × 20 mL), dried over Na₂SO₄, and evaporated. The crude product was purified by adsorptive filtration on silica gel (short column, *n*-hexane-acetone 19:1, v/v) to afford 3,7,4'-triallylisomacarangin (**6a**) (12.6 mg, 37.4%) and 3,6,7,4'-tetraallylisomacarangin (**6b**) (6.5 mg, 17.4%) as a yellowish powder.

3,7,4'-Triallylisomacarangin (6a): ¹H NMR (500 MHz, acetone- d_6 , 25 °C, TMS): $\delta = 6.74$ (s, 1H, H-6), 8.13 (d, J = 9.0 Hz, 2H, H-2'/H-6'), 7.12 (d, J = 9.0 Hz, 2H, H-3'/H-5'), 3.38 (d, J = 7.2 Hz, 2H, H-1"), 5.26 (d, J = 1.5 Hz, 1H, H-2"), 1.96 (dd, J = 9.1, 6.3 Hz, 2H, H-4"), 2.05 (s, 2H, H-5"), 5.07 (m, 1H, H-6"), 1.55 (s, 3H, H-8"), 1.60 (d, J = 1.7 Hz, 3H, H-9"), 1.79 (d, J = 1.3 Hz, 3H, H-10"), 3-O-allyl [4.55 (d, J = 6.0 Hz, 2H), 6.00 (m, 1H), 5.30 (m, 2H)], 7-O-allyl [4.75 (d, J = 6.0, Hz, 2H), 5.16 (m, 1H), 5.50 (m, 2H)], 4'-O-allyl [4.69 (d, J = 6.0, Hz, 2H), 6.13 (m, 1H), 5.50 (m, 2H)],—¹³C NMR (125 MHz, acetone- d_6) $\delta = 156.7$ (C-2), 138.2 (C-3), 179.3 (C-4), 156.0 (C-5), 91.7 (C-6), 163.0 (C-7), 113.0 (C-8), 158.6 (C-8a), 106.4 (C-4a), 123.9 (C-1'), 131.1 (C-2'/C-6'), 115.4 (C-3'/C-5'), 161.6 (C-4'), 22.0 (C-1"), 122.9 (C-2"), 135.5 (C-3"), 40.2 (C-4"), 27.3 (C-5"), 125.1 (C-6"), 131.6 (C-7"), 17.8 (C-8"), 25.7 (C-9"), 16.3 (C-10"), 3-O-allyl [73.7 (CH₂), 134.8 (CH), 118.3 (CH₂)], 7-O-allyl [70.0 (CH₂), 133.8 (CH), 117.8 (CH₂)], 4'-O-allyl [69.5 (CH₂), 134.2 (CH), 117.9 (CH₂)]; HRESIMS [M + Na]⁺ at m/z 565.2560 (calcd. m/z 565.2560 for C₃₄H₃₈O₆Na⁺).

3,6,7,4'-Tetraallylisomacarangin (**6b**): ¹H NMR (500 MHz, acetone- d_6 , 25 °C, TMS): $\delta = 8.17$ (d, J = 9.0 Hz, 2H, H-2'/H-6'), 7.14 (d, J = 9.0 Hz, 2H, H-3'/H-5'), 3.41 (d, J = 6.8 Hz, 2H, H-1"), 5.28 (m, 1H), 1.93 (t, J = 7.3 Hz, 2H, H-4"), 2.00 (t, J = 7.3 Hz, 2H, H-5"), 5.06 (s, 1H, H-6"), 1.54 (s, 3H, H-8"), 1.59 (d, J = 1.5 Hz, 3H, H-9"), 1.77 (s, 3H, H-10"), 3-O-allyl [4.75 (d, J = 6.0 Hz, 2H), 5.16 (m, 1H), 5.50 (m, 2H)], 6-C-allyl [3.64 (m, 2H), 6.05 (m, 1H), 7.14 (m, 2H)], 7-O-allyl [4.45 (d, J = 6.0, Hz, 2H), 5.90 (m, 1H), 5.26 (m, 2H)], 4'-O-allyl [4.70 (d, J = 6.0, Hz, 2H), 6.12 (m, 1H), 5.17 (m, 2H)]—¹³C NMR (125 MHz, acetone- d_6) $\delta = 158.3$ (C-2), 138.2 (C-3), 178.7 (C-4), 157.3 (C-5), 112.3 (C-6), 162.1 (C-7), 112.3 (C-8), 153.2 (C-8a), 108.7 (C-4a), 124.0 (C-1'), 131.3 (C-2'/C-6'), 115.6 (C-3'/C-5'), 161.8 (C-4'), 23.1 (C-1"), 123.5 (C-9"), 135.8 (C-3"), 39.6 (C-4"), 27.2 (C-5"), 125.0 (C-6"), 131.7 (C-7"), 17.4 (C-8"), 25.8 (C-9"), 16.4 (C-10"), 3-O-allyl [73.7 (CH₂), 134.8 (CH), 118.4 (CH₂)], 6-C-allyl [28.5 (CH₂), 137.3 (CH), 115.7 (CH₂)], 7-O-allyl [76.1 (CH₂), 134.7 (CH), 117.4 (CH₂)], 4'-O-allyl [69.4 (CH₂), 134.2 (CH), 117.9 (CH₂)]; HRESIMS [M + H]⁺ at *m*/z 583.3052 (calcd. *m*/z 583.3054 for C₃₇H₄₃O₆⁺).

3.5.2. Acetylation of Isomacarangin (6)

Pyridine (5 mL) was added to a powder of isomacarangin (6) (25.1 mg, 0.059 mmol) and then acetic anhydride (3 mL) was added. The mixture was magnetically stirred at 25 °C and monitored by TLC until the disappearance of the starting material. After 24 h of reaction, it was poured into ice (100 g) and extracted with EtOAc (3 × 10 mL). The organic layer was washed with water (3 × 20 mL), dried over Na₂SO₄, and evaporated. The crude product was purified by adsorptive filtration on silica gel (short column, *n*-hexane–acetone 17:3, *v*/*v*) to yield 3,5,7,4'-tetraacetylisomacarangin (6c) (34.9 mg, 100%) as a yellowish powder.

3,5,7,4'-Tetraacetylisomacarangin (6c): ¹H-NMR (500 MHz, acetone- d_6 , 25 °C, TMS): $\delta = 8.31$ (s, 1H, H-6), 8.81 (d, J = 8.8 Hz, 2H, H-2'/H-6'), 8.16 (d, J = 8.8 Hz, 2H, H-3'/H-5'), 4.13 (br s, 2H, H-1''), 5.83 (m, 1H, H-2''), 2.76/2.84 (m, 2H, H-4''), 2.83 (m, 2H, H-5''), 5.86 (m, 1H, H-6''), 2.58 (s, 3H, H-8''), 2.42 (s, 3H, H-9''), 2.36 (s, 3H, H-10''), 2.31 (3-CH₃C=O), 2.32 (5-CH₃C=O), 2.39 (7-CH₃C=O), 2.40 (4'-CH₃C=O).—¹³C NMR (125 MHz, acetone- d_6)
$$\begin{split} &\delta = 154.3 \ (\text{C-2}), \ 134.6 \ (\text{C-3}), \ 170.5 \ (\text{C-4}), \ 149.0 \ (\text{C-5}), \ 111.7 \ (\text{C-6}), \ 155.2 \ (\text{C-7}), \ 126.4 \ (\text{C-8}), \\ &155.6 \ (\text{C-8a}), \ 115.4 \ (\text{C-4a}), \ 127.9 \ (\text{C-1}'), \ 130.6 \ (\text{C-2}'/\text{C-6}'), \ 123.2 \ (\text{C-3}'/\text{C-5}'), \ 154.2 \ (\text{C-4}'), \ 23.8 \ (\text{C-1}''), \ 121.6 \ (\text{C-2}''), \ 136.9 \ (\text{C-3}''), \ 40.3 \ (\text{C-4}''), \ 27.2 \ (\text{C-5}''), \ 124.9 \ (\text{C-6}''), \ 131.8 \ (\text{C-7}''), \ 17.7 \ (\text{C-8}''), \ 25.7 \ (\text{C-9}''), \ 16.4 \ (\text{C-10}''), \ 20.4/169.4 \ (3-\text{CH}_3\text{C=O}), \ 21.1/168.3 \ (5-\text{CH}_3\text{C=O}), \ 20.4/169.2 \ (7-\text{CH}_3\text{C=O}), \ 21.0/168.4 \ (4'-\text{CH}_3\text{C=O}); \ \text{HRESIMS} \ [\text{M} + \text{Na}]^+ \ \text{at} \ m/z \ 613.2043 \ (\text{calcd.} \ m/z \ 613.2044 \ \text{for} \ \text{C}_{33}\text{H}_{34}\text{O}_{10}\text{Na}^+). \end{split}$$

3.6. Antimicrobial Assays

3.6.1. Antibacterial Activity

The screenings were performed in duplicate three times in sterile 96 well microplates. Indeed, 98 μ L and 95 μ L of MHB culture medium were introduced into the first wells corresponding to the extracts and compounds, respectively, and 50 µL was introduced into the rest of the wells. Subsequently, 2 µL of a sterile solution of extracts concentrated at 100 mg/mL and 5 μ L of a solution of compounds concentrated at 20 mg/mL were taken and introduced into the corresponding wells followed by a serial of four dilutions of geometric order 2. Finally, 50 μ L of a bacterial suspension at a load of 10⁶ cells/mL was distributed in the test wells and those of the negative control. The concentrations of extract, fractions, and compounds in wells ranged from 1000 μ g/mL to 62.5 μ g/mL, $500 \ \mu g/mL$ to $31.25 \ \mu g/mL$, respectively, and from $0.25 \ \mu g/mL$ to $0.0153 \ \mu g/mL$, for the ciprofloxacin used as positive controls. The final charge of the inoculum in each well was 5×10^5 cells/mL with 200 μ L as the final volume. The sterility control was constituted only of the culture medium. The positive control consisted of the culture medium, inoculum, and ciprofloxacin. The microplates were covered and then incubated at 37 °C for 24 h. At the end of the incubation period, 10 μ L of a freshly prepared resazurin solution (0.15 mg/mL) was added to all wells, and the plates were once again incubated under the same conditions for 30 min. The smallest concentration at which there was no change in coloration from blue to pink corresponding to a lack of visible bacterial growth was considered as the MIC.

3.6.2. Antifungal Activity

The screenings were performed in duplicate in sterile 96 well microplates. Indeed, $96 \,\mu\text{L}$ and $95 \,\mu\text{L}$ of SDB culture medium were introduced into the first wells corresponding to the compounds, fractions, and extracts, respectively, and 50 µL was introduced into the rest of the wells. Subsequently, 5 µL of a sterile solution of compounds concentrated at 20 mg/mL and 4 μ L of a sterile solution of extracts concentrated at 100 mg/mL were taken and introduced into the corresponding wells, followed by a serial of five geometric dilutions of order 2. Finally, 50 μ L of a fungal suspension at a load of 2 \times 10⁴ cells/mL was distributed in the test wells and those of the negative control. Concentrations of extracts, compounds, and fluconazole in the wells ranged from 2000 μ g/mL to 62.5 μ g/mL, 500 μ g/mL to 3.890 μ g/mL, and from 1.25 μ g/mL to 0.0383 μ g/mL, respectively, and the final charge of the inoculum in each well was 10^4 cells/mL. The sterility control was constituted only of the culture medium. The positive control consisted of the culture medium, inoculum, and fluconazole. The microplates were covered and then incubated at $37 \,^{\circ}\text{C}$ for 48 h. At the end of the incubation period, 10 μ L of a freshly prepared resazurin solution (0.15 mg/mL) was added to all wells and the plates were once again incubated under the same conditions for 30 min. The smallest concentration at which there was no change in coloration from blue to pink corresponding to a lack of visible fungal growth was considered as the MIC.

Supplementary Materials: The following supporting information can be downloaded at: https: //www.mdpi.com/article/10.3390/molecules27248820/s1, Figure S1: ESI-HR Mass spectrum of **6a**; Figure S2: IR spectrum of **6a**; Figure S3: 1H-NMR (500 MHz, acetone $-d_6$) spectrum of **6a**; Figure S4: ¹³C-NMR (125 MHz, acetone $-d_6$) spectrum of **6a**; Figure S5: DEPT 135 spectrum of **6a**; Figure S6: ¹H-¹H COSY spectrum of **6a**; Figure S7: HSQC spectrum of **6a**; Figure S8: HMBC spectrum of **6a**; Figure S9: ESI-HR Mass spectrum of **6b**; Figure S10: ¹H-NMR (500 MHz, acetone $-d_6$) spectrum of **6b**; Figure S11: ¹³C-NMR (125 MHz, acetone $-d_6$) spectrum of **6b**; Figure S12: DEPT 135 spectrum of **6b**; Figure S13: ¹H-¹H COSY spectrum of **6b**; Figure S14: HSQC spectrum of **6b**; Figure S15: HMBC spectrum of **6b**; Figure S16: ESI-HR Mass spectrum of **6c**; Figure S17: ¹H-NMR (500 MHz, acetone $-d_6$) spectrum of **6c**; Figure S18: ¹³C-NMR (125 MHz, acetone $-d_6$) spectrum of **6c**; Figure S19: DEPT 135 spectrum of **6c**; Figure S20: ¹H-¹H COSY spectrum of **6c**; Figure S21: HSQC spectrum of **6c**; Figure S22: HMBC spectrum of **6c**; Figure S23–S57: ¹H and ¹³C-NMR data of compounds **1–17**; Scheme S1: Protocol of extraction and isolation of compounds from *M. occidentalis*

Author Contributions: Conceptualization, G.W.F. and B.T.N.; Methodology, V.F.K.K., C.C.S.F., G.W.F. and B.T.T.; Software, V.F.K.K., B.T.T. and I.M.K.M.; Validation, G.W.F., B.N.L., M.F., F.F.B. and N.S.; Formal analysis, G.W.F. and B.T.T.; Investigation, V.F.K.K., C.C.S.F. and I.M.K.M.; Writing—original draft preparation, V.F.K.K., C.C.S.F. and I.M.K.M.; Writing—review and editing, V.F.K.K., C.C.S.F., G.W.F., B.N.L. and F.F.B.; Supervision, G.W.F. and B.T.N.; Project administration, G.W.F., B.T.N., M.F., B.N.L. and N.S.; Funding acquisition, N.S. and B.N.L. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the Yaoundé-Bielefeld Graduate School of Natural Products with Antiparasitic and Antibacterial Activities YaBiNaPA, grant number 57316173. The APC was funded by the Open Access Publication Fund of Bielefeld University and the Deutsche Forschungsgemeinschaft (DFG).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: The authors would like to acknowledge the Yaoundé-Bielefeld Graduate School of Natural Products with Antiparasitic and Antibacterial Activities (YaBiNaPA, project no. 57316173) and the support of the University of Bielefeld in Germany. We also acknowledge support for the publication costs by the Open Access Publication Fund of Bielefeld University and the Deutsche Forschungsgemeinschaft (DFG).

Conflicts of Interest: The authors declare no conflict of interest.

Sample Availability: Samples of the compounds are available from the authors.

References

- Yadav, S.; Kapley, A. Antibiotic resistance: Global health crisis and metagenomics. *Biotechnol Rep.* 2021, 29, e00604. [CrossRef] [PubMed]
- Aslam, B.; Wang, W.; Arshad, M.I.; Khurshid, M.; Muzammil, S.; Rasool, M.H.; Nisar, M.A.; Alvi, R.F.; Aslam, M.A.; Qamar, M.U.; et al. Antibiotic resistance: A rundown of a global crisis. *Infect. Drug. Resist.* 2018, *11*, 1–14. [CrossRef] [PubMed]
- Jouogo, N.D.C.; Tamokou, J.D.D.; Teponno, R.B.; Matsuete-Takongmo, G.; Voutquenne-Nazabadioko, L.; Tapondjou, L.A.; Ngnokam, D. Chemotaxonomy and antibacterial activity of the extracts and chemical constituents of *Psychotria succulenta* Hiern. (Rubiaceae). *Biomed Res. Int.* 2022, 2022, 1–10. [CrossRef]
- 4. Stafford, A.M. Plant cell cultures as a source of bioactive small molecules. Curr. Opin. Drug Discov. Dev. 2002, 5, 296–303.
- 5. Magadula, J.J. Phytochemistry and pharmacology of the genus *Macaranga*: A review. J. Med. Plant. Res. 2014, 8, 489–503. [CrossRef]
- Segun, P.A.; Ogbole, O.O.; Ismail, F.M.; Nahar, L.; Evans, A.R.; Ajaiyeoba, E.O.; Sarker, S.D. Bioassay-guided isolation and structure elucidation of cytotoxic stilbenes and flavonols from the leaves of *Macaranga barteri*. *Fitoterapia* 2019, 134, 151–157. [CrossRef]
- Schutz, B.A.; Wright, A.D.; Rali, T.; Sticher, O. Prenylated flavanones from the leaves of *Macaranga pleiostemona*. *Phytochemistry* 1995, 40, 1273–1277. [CrossRef]
- Péresse, T.; Jézéquel, G.; Allard, P.M.; Pham, V.C.; Huong, D.T.; Blanchard, F.; Bignon, J.; Lévaique, H.; Wolfender, J.-L.; Litaudon, M.; et al. Cytotoxic prenylated stilbenes isolated from *Macaranga tanarius*. J. Nat. Prod. 2017, 80, 2684–2691. [CrossRef]
- Kawakami, S.; Harinantenaina, L.; Matsunami, K.; Otsuka, H.; Shinzato, T.; Takeda, Y. Macaflavanones A-G, prenylated flavanones from the leaves of *Macaranga tanarius*. J. Nat. Prod. 2008, 71, 1872–1876. [CrossRef]
- Darmawan, A.; Kosela, S.; Kardono, L.B.; Syah, Y.M. Scopoletin, a coumarin derivative compound isolated from *Macaranga* gigantifolia. J. Appl. Pharm. Sci. 2012, 2, 175–177.
- Ngoumfo, R.M.; Ngounou, G.E.; Tchamadeu, C.V.; Qadir, M.I.; Mbazoa, C.D.; Begum, A.; Ngninzeko, F.N.; Lontsi, D.; Choudhary, M.I. Inhibitory effect of macabarterin, a polyoxygenated ellagitannin from *Macaranga barteri*, on human neutrophil respiratory burst activity. J. Nat. Prod. 2008, 71, 1906–1910. [CrossRef] [PubMed]

- 12. Tabopda, T.K.; Fotso, G.W.; Ngoupayo, J.; Mitaine-Offer, A.C.; Ngadjui, B.T.; Lacaille-Dubois, M.A. Antimicrobial dihydroisocoumarins from *Crassocephalum biafrae*. *Planta*. *Med*. **2009**, *75*, 1258–1261. [CrossRef] [PubMed]
- 13. Fotso, G.W.; Kamdem, L.M.; Dube, M.; Fobofou, S.A.; Ebene, A.N.; Arnold, N.; Ngadjui, B.T. Antimicrobial secondary metabolites from the stem barks and leaves of *Monotes kerstingii* Gilg (Dipterocarpaceae). *Fitoterapia* **2019**, *137*, 104239. [CrossRef] [PubMed]
- 14. Minarti; Cahyana, A.H.; Darmawan, A. Secondary metabolite compound isolated from the leaves of *Macaranga magna* Turrill. In *AIP Conference Proceedings*; AIP Publishing LLC: Melville, NY, USA, 2019; Volume 2175, p. 020029. [CrossRef]
- Bouzeko, I.L.T.; Dongmo, F.L.M.; Ndontsa, B.L.; Ngansop, C.A.N.; Keumoe, R.; Bitchagno, G.T.M.; Jouda, J.B.; Mbouangouere, R.; Tchegnitegni, B.T.; Boyom, F.F.; et al. Chemical constituents of *Mussaenda erythrophylla* Schumach. & Thonn. (Rubiaceae) and their chemophenetic significance. *Biochem. Syst. Ecol.* 2021, *98*, 104329. [CrossRef]
- 16. Thang, P.T.; Dung, N.A.; Giap, T.H.; Oanh, V.T.K.; Hang, N.T.M.; Huong, T.T.; Thanh, L.N.; Huong, D.T.M.; Van, C.P. Preliminary study on the chemical constituents of the leaves of *Macaranga balansae* Gagnep. *Vietnam J. Chem.* **2018**, *56*, 632–636. [CrossRef]
- 17. Tian, Y.; Liu, X.Q.; Dong, J.X. Apigenin glycosides from *Euphorbia humifusa* wild. *Acta Pharm. Sin.* **2009**, *44*, 496–499.
- Huonga, D.T.M.; Anh, L.T.; Cuc, N.T.; Nhiem, N.X.; Tai, B.H.; Van Kiem, P.; Litaudon, M.; Dang, T.T.; Chau, M.V.; Pham, V.C. Cytotoxic prenylated flavonoids from the leaves of *Macaranga indica*. *Phytochem. Lett.* 2019, 34, 39–42. [CrossRef]
- Beutler, J.A.; Shoemaker, R.H.; Johnson, T.; Boyd, M.R. Cytotoxic geranyl stilbenes from *Macaranga schweinfurthii*. J. Nat. Prod. 1998, 61, 1509–1512. [CrossRef]
- Atta-Ur-Rahman; Ngounou, F.N.; Choudhary, M.I.; Malik, S.; Makhmoor, T.; Nur-E-Alam, M.; Zareen, S.; Lontsi, D.; Ayafor, J.F.; Sondengam, B.L. New antioxidant and antimicrobial ellagic acid derivatives from *Pteleopsis hylodendron*. *Planta*. *Med.* 2001, 67, 335–339. [CrossRef]
- Li, X.C.; Elsohly, H.N.; Hufford, C.D.; Clark, A.M. NMR assignments of ellagic acid derivatives. *Magn. Reson. Chem.* 1999, 37, 856–859. [CrossRef]
- Zhang, S.; Liu, X.; Zhang, Z.L.; He, L.; Wang, Z.; Wang, G.S. Isolation and identification of the phenolic compounds from the roots of *Sanguisorba officinalis* L. and their antioxidant activities. *Molecules* 2012, *17*, 13917–13922. [CrossRef] [PubMed]
- 23. Pojchaijongdee, N.; Sotanaphun, U.; Limsirichaikul, S.; Poobrasert, O. Geraniinic acid derivative from the leaves of *Phyllanthus reticulatus*. *Pharm. Biol.* **2010**, *48*, 740–744. [CrossRef] [PubMed]
- Hawas, U.W. Antioxidant activity of brocchlin carboxylic acid and its methyl ester from *Chrozophora brocchiana*. *Nat. Prod. Res.* 2007, 21, 632–640. [CrossRef]
- 25. Zou, Y.; Li, Y.; Kim, M.M.; Lee, S.H.; Kim, S.K. Ishigoside, a new glyceroglycolipid isolated from the brown alga *Ishige okamurae*. *Biotechnol. Bioprocess Eng.* **2009**, *14*, 20–26. [CrossRef]
- Kuete, V. Potential of Cameroonian plants and derived products against microbial infections: A review. *Planta. Med.* 2010, 76, 1479–1491. [CrossRef] [PubMed]
- 27. Widyawati, P.S.; Budianta, T.D.W.; Kusuma, F.A.; Wijaya, E.L. Difference of solvent polarity to phytochemical content and antioxidant activity of *Pluchea indicia* less leaves extracts. *Int. J. Pharmacogn. Phytochem. Res.* **2014**, *6*, 850–855.
- 28. Lim, T.Y.; Lim, Y.Y.; Yude, C.M. Evaluation of antioxidant, antibacterial and anti-tyrosinase activities of four *Macaranga* species. *Food chem.* **2009**, *114*, 594–598. [CrossRef]
- 29. Lim, T.Y.; Yude, C.M. Bioactivity of leaves of *Macaranga* species in tropical peat swamp and non-peat swamp environments. *J. Trop. For. Sci.* **2014**, *26*, 134–141.
- Salah, M.A.; Bedir, E.; Toyang, N.J.; Khan, I.A.; Harries, M.D.; Wedge, D.E. Antifungal clerodane from *Macaranga monandra* (L) Muell.et Arg. (Euphorbiaceae). J. Agric. Food Chem. 2003, 517, 7607–7610. [CrossRef]
- Osorio, M.; Carvajal, M.; Vergara, A.; Butassi, E.; Zacchino, S.; Mascayano, C.; Montoya, M.; Mejías, S.; Cortez-San, M.M.; Vásquez-Martínez, Y. Prenylated flavonoids with potential antimicrobial activity: Synthesis, biological activity, and in silico study. *Int. J. Mol. Sci.* 2021, 22, 5472. [CrossRef] [PubMed]
- Sohn, H.Y.; Son, K.H.; Kwon, C.S.; Kwon, G.S.; Kang, S.S. Antimicrobial and cytotoxic activity of 18 prenylated flavonoids isolated from medicinal plants: *Morus alba* L., *Morus mongolica* Schneider, *Broussnetia papyrifera* (L.) Vent, *Sophora flavescens* Ait and *Echinosophora koreensis* Nakai. *Phytomedicine* 2004, 11, 666–672. [CrossRef] [PubMed]
- Alhassan, A.M.; Abdullahi, M.I.; Uba, A.; Umar, A. Prenylation of aromatic secondary metabolites: A new frontier for development of novel drugs. *Trop. J. Pharm. Res.* 2014, 13, 307–314. [CrossRef]
- Botta, B.; Vitali, A.; Menendez, P.; Misiti, D.; Monache, D.D. Prenylated flavonoids: Pharmacology and biotechnology. Curr. Med. Chem. 2005, 12, 717–739. [CrossRef]
- 35. Fotso, G.W.; Ngameni, B.; Storr, T.E.; Ngadjui, B.T.; Mafu, S.; Stephenson, G.R. Synthesis of novel stilbene–coumarin derivatives and antifungal screening of *Monotes kerstingii*-specialized metabolites against *Fusarium oxysporum*. *Antibiotics* **2020**, *9*, 537. [CrossRef] [PubMed]
- 36. Tanaka, T.; Iinuma, M.; Asai, F.; Ohyama, M.; Burandt, C.L. Flavonoids from the root and stem of *Sophora tomentosa*. *Phytochemistry* **1997**, *46*, 1431–1437. [CrossRef]
- Beutler, J.A.; McCall, K.L.; Boyd, M.R. A novel geranylflavone from *Macaranga schweinfurthii*. Nat.Prod. Lett. 1999, 13, 29–32. [CrossRef]
- Subramani, K.; Karnan, R.; Sajitha, M.; Anbarasan, P.M. New and rare acylated flavone glycosides from the aerial parts of Chrozophoro rottleri. J. Biochem. 2013, 7, 102–106.

- 39. Zakaria, I.; Ahmat, N.; Jaafar, F.M.; Widyawaruyanti, A. Flavonoids with antiplasmodial and cytotoxic activities of *Macaranga triloba*. *Fitoterapia* **2012**, *83*, 968–972. [CrossRef]
- Matsunami, K.; Takamori, I.; Shinzato, T.; Aramoto, M.; Kondo, K.; Otsuka, H.; Takeda, Y. Radical-scavenging activities of new megastigmane glucosides from *Macaranga tanarius* (L) MÜLL.-ARG. *Chem. Pharm. Bull.* 2006, 54, 1403–1407. [CrossRef]
- Mouzié, C.M.; Guefack, M.G.F.; Kianfé, B.Y.; Serondo, H.U.; Ponou, B.K.; Siwe-Noundou, X.; Teponno, R.B.; Krause, R.W.M.; Kuete, V.; Tapondjou, L.A. A new chalcone and antimicrobial chemical constituents of *Dracaena stedneuri*. *Pharmaceuticals* 2022, 15, 725. [CrossRef]
- 42. Dube, M.; Llanes, D.; Saoud, M.; Rennert, R.; Imming, P.; Haeberli, C.; Keiser, J.; Arnold, N. Albatrellus confluens (Alb. & Schwein.) Kotl. & Pouz. Natural fungal compounds and synthetic derivatives with in vitro anthelmintic activities and antiproliferative effects against two human cancer cell lines. *Molecules* 2022, 27, 2950. [CrossRef] [PubMed]
- Nkuété, A.H.L.; Kuete, V.; Gozzini, D.; Migliolo, L.; Oliveira, A.L.; Wabo, H.K.; Tane, P.; Vidari, G.; Efferth, T.; Franco, O.L. Anti-leukemia activity of semisynthetic phenolic derivatives from *Polygonum limbatum* Meisn. *Chem. Cent. J.* 2015, *9*, 1–8. [CrossRef] [PubMed]